Should I Buy CRDF? CRDF 2026 Analysis

Should You Buy Cardiff Oncology Inc (CRDF) Today? Analysis, Price Targets, and 2026 Outlook.

No data

Growth

Profitability

Efficiency

6 Analyst Rating

Wall Street analysts forecast CRDF stock price to rise

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.600

Low

Averages

13.67

High

Current: 1.600

Low

Averages

13.67

High

Piper Sandler

Overweight

NULL

downgrade

$10 -> $6

AI Analysis

2026-02-25

Reason

Piper Sandler

Price Target

$10 -> $6

AI Analysis

2026-02-25

downgrade

Overweight

NULL

Reason

Piper Sandler lowered the firm's price target on Cardiff Oncology to $6 from $10 and keeps an Overweight rating on the shares. The firm notes Cardiff ended 2025 with cash of $58.3M to fund operations into Q1 2027. Piper is pushing out onvansertib approval to 2030, removing value for other cancers and rolling forward its discount period to mid-2027.

H.C. Wainwright

Buy

maintain

$10

2026-01-28

Reason

H.C. Wainwright

Price Target

$10

2026-01-28

maintain

Buy

Reason

H.C. Wainwright says the selloff yesterday in shares of Cardiff Oncology brings an attractive entry point. The firm finds updated CRDF-004 trial results "highly encouraging." It expects a more mature clinical dataset from the CRDF-004 study in the first half of 2026. The market "overreaction provides an attractive entry point," says H.C. Wainwright. The analyst keeps a Buy rating on Cardiff Oncology with a $10 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRDF

Unlock Now

CRDF Should I Buy

CRDF Should I Buy

Should You Buy Cardiff Oncology Inc (CRDF) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

Growth

Profitability

Efficiency

People Also Watch